SBP GROUP(01177)

5.250-0.020-0.38%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Movement Alert｜SBP GROUP Intraday Rise 3.23% in Regular Trading, Hepatitis B pipeline updates and share buyback support sentiment
  Market Focus · 10-16
  Movement Alert｜SBP GROUP Intraday Rise 3.23% in Regular Trading, Hepatitis B pipeline updates and share buyback support sentiment
- Sino Biopharmaceutical Stock Climbs 2.0% in Hong Kong, Outperforms Competitors
  Dow Jones · 10-15
  Sino Biopharmaceutical Stock Climbs 2.0% in Hong Kong, Outperforms Competitors
- Movement Alert｜SBP GROUP Intraday Rise 3.1% in Regular Trading, innovation drug sentiment and AASLD data catalyst support shares
  Market Focus · 10-15
  Movement Alert｜SBP GROUP Intraday Rise 3.1% in Regular Trading, innovation drug sentiment and AASLD data catalyst support shares
- SBP GROUP Shares Climb Nearly 3% as Latest TQ-A3334 and Bepirovirsen Research Findings Set to Be Unveiled at 2026 AASLD
  Stock News · 10-15
  SBP GROUP Shares Climb Nearly 3% as Latest TQ-A3334 and Bepirovirsen Research Findings Set to Be Unveiled at 2026 AASLD
- Sino Biopharma Unit to Present Results of Two Hepatitis B Virus Drugs at Liver Disease Conference
  MT Newswires Live · 10-14
  Sino Biopharma Unit to Present Results of Two Hepatitis B Virus Drugs at Liver Disease Conference
- Movement Alert｜SBP GROUP Falls 3.08% in Regular Trading, Sector Weakness Overshadows Recent Share Buyback
  Market Focus · 10-14
  Movement Alert｜SBP GROUP Falls 3.08% in Regular Trading, Sector Weakness Overshadows Recent Share Buyback
- Movement Alert｜SBP GROUP Falls 3.15% in Regular Trading, Innovative Drug Sector Broadly Weak
  Market Focus · 10-13
  Movement Alert｜SBP GROUP Falls 3.15% in Regular Trading, Innovative Drug Sector Broadly Weak
- Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong
  Dow Jones · 10-09
  Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong
- Hong Kong Regulators Issue Joint Statement on Audit Opinions; Nasdaq Slides 1.25%
  Stock News · 10-09
  Hong Kong Regulators Issue Joint Statement on Audit Opinions; Nasdaq Slides 1.25%
- Sino Biopharma Unit Completes Patient Enrollment for Pulmonary Disease Drug Trial
  MT Newswires Live · 10-08
  Sino Biopharma Unit Completes Patient Enrollment for Pulmonary Disease Drug Trial
- SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing
  Stock News · 10-08
  SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing
- Sino Biopharmaceutical Stock Slides 3.3% in Hong Kong
  Dow Jones · 10-08
  Sino Biopharmaceutical Stock Slides 3.3% in Hong Kong
- Movement Alert｜SBP GROUP Falls 3.08% in Regular Trading, Following Sector Adjustment
  Market Focus · 10-08
  Movement Alert｜SBP GROUP Falls 3.08% in Regular Trading, Following Sector Adjustment
- Hong Kong Stocks Climb, Led by Pharmaceutical, Tech Stocks
  Reuters · 10-06
  Hong Kong Stocks Climb, Led by Pharmaceutical, Tech Stocks
- Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts
  Stock News · 10-06
  Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts
- HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High
  Tiger Newspress · 10-06
  HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High
- Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Citigroup Retains Buy Rating on STADA Collaboration
  Market Focus · 10-06
  Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Citigroup Retains Buy Rating on STADA Collaboration
- Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors
  Dow Jones · 10-02
  Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors
- Movement Alert｜SBP GROUP Falls 4.29% in Regular Trading, Trading at HK$5.48
  Market Focus · 10-02
  Movement Alert｜SBP GROUP Falls 4.29% in Regular Trading, Trading at HK$5.48
- Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong
  Dow Jones · 09-30
  Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong
Company Profile
Company Name
SBP GROUP
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.sinobiopharm.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
- 09-24
  Interim Report
  2026 INTERIM REPORT
  2026 INTERIM REPORT
- 08-19
  Interim Report
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- 04-29
  Annual Report
  2025 ANNUAL REPORT
  2025 ANNUAL REPORT

1D
5D
Day
Week
Month

Loading ...

High

5.495

Open

5.400

Volume%

1.29

Low

5.140

5.270

T/O Rate

0.45%

To The Moon

SBP GROUP(01177)

Company Profile

Most Discussed